The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: The NOBORI PK study
Key result
Biolimus A9 eluted from Nobori coronary stents resulted in very low systemic exposure, with only 30% of patients having quantifiable blood concentrations at 28 days (maximum 32.2 pg/mL).
Population
20 patients with coronary artery disease
Design
Cohort
Follow-up
9 months
Authors
Discussion
Loading...
Member takes
Implication
Indicates minimal systemic exposure with Nobori stents; leaves open whether this improves safety versus other drug-eluting stents.
Structured PICO
P
Population
20 patients with coronary artery disease treated with a single 14-mm or 28-mm long Nobori stent, followed for up to 9 months.
I
Intervention
Nobori coronary stents eluting Biolimus A9 (single 14-mm or 28-mm long stent)
O
Outcome
Systemic blood concentrations of Biolimus A9 after 28 days and 6 months as measured using liquid chromatography-tandem mass spectrometry assaysurrogate
Biolimus A9 eluted from Nobori coronary stents results in very low systemic exposure and is well tolerated in patients with coronary artery disease.
Cite This Study
Ostojić et al. (2008) studied coronary artery disease (n=20). Biolimus A9 eluted from Nobori coronary stents was evaluated on systemic blood concentrations of Biolimus A9 after 28 days and 6 months. Biolimus A9 eluted from Nobori coronary stents resulted in very low systemic exposure, with only 30% of patients having quantifiable blood concentrations at 28 days (maximum 32.2 pg/mL).